Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Active-specific immunotherapy for melanoma.

M S Mitchell1, W Harel, R A Kempf

  • 1Department of Medicine, University of Southern California School of Medicine, Los Angeles.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|May 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing durations of intrauterine balloon placement for intrauterine adhesions after hysteroscopic surgery: a systematic review and meta-analysis.

BMC pregnancy and childbirth·2026
Same author

Interdisciplinary Tools to Safeguard and Amplify Aquatic Genetic Resource Use: A Foundation for Industrial-Scale Quality Control for Fertilization.

Animals : an open access journal from MDPI·2026
Same author

Primary signet ring cell carcinoma of the female urethra: A case report.

World journal of clinical cases·2025
Same author

Evolution of radiology staff perspectives during artificial intelligence (AI) implementation for expedited lung cancer triage.

Clinical radiology·2024
Same author

Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.

ESMO open·2024
Same author

Artificial intelligence (AI) implementation within the National Health Service (NHS): the South West London AI Working Group experience.

Clinical radiology·2024
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

This study shows that a therapeutic vaccine using melanoma cell lysates and DETOX adjuvant can induce immune responses and disease regression in metastatic melanoma patients, with minimal toxicity. The treatment led to remissions and improved survival in some patients, correlating with increased cytolytic T cells.

Area of Science:

  • Immunology
  • Oncology
  • Vaccine Development

Background:

  • Metastatic melanoma remains a significant challenge in cancer treatment.
  • Therapeutic vaccines offer a potential strategy for active immunotherapy against cancer.

Purpose of the Study:

  • To evaluate the clinical efficacy and immunogenicity of a novel therapeutic vaccine for metastatic melanoma.
  • To assess the safety and toxicity profile of the vaccine regimen.

Main Methods:

  • Twenty-five patients with metastatic melanoma received a vaccine of allogeneic melanoma lysates plus DETOX adjuvant over six weeks.
  • Clinical responses, duration of remission, survival, and immune cell changes (cytolytic T cells) were monitored.
  • Toxicity and adverse events were recorded.

Related Experiment Videos

Main Results:

  • One complete remission, three partial remissions, and long-term stability were observed in 25 patients.
  • Responsive sites included skin, ileal, breast, and liver metastases.
  • Increased precursors of cytolytic T cells (CTLs) correlated with positive clinical outcomes.
  • Toxicity was minimal, primarily injection site soreness; severe granulomas occurred in five patients.

Conclusions:

  • Active-specific immunization with melanoma lysates and DETOX adjuvant can induce anti-melanoma immunity.
  • The vaccine demonstrated the potential to induce disease regression in a subset of patients with metastatic melanoma.
  • The treatment was generally well-tolerated, suggesting a favorable safety profile for this immunotherapeutic approach.